Sernova Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Sernova de 61.4% y 60.2% respectivamente, mientras que el BPA crecerá en un 60.4% al año.

Información clave

61.4%

Tasa de crecimiento de los beneficios

60.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	34.0%
Tasa de crecimiento de los ingresos	60.2%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	15 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Feb 23

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Aug 11

Previsiones de crecimiento de beneficios e ingresos

TSX:SVA - Estimaciones futuras de los analistas y datos financieros pasados (CAD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
10/31/2027	76	26	N/A	N/A	2
10/31/2026	0	-27	N/A	N/A	3
10/31/2025	10	-16	-1	-1	3
10/31/2024	N/A	-38	-23	-23	4
7/31/2024	N/A	-39	-26	-26	N/A
4/30/2024	N/A	-41	-27	-27	N/A
1/31/2024	N/A	-41	-29	-29	N/A
10/31/2023	N/A	-39	-30	-30	N/A
7/31/2023	N/A	-36	-24	-24	N/A
4/30/2023	N/A	-31	-24	-24	N/A
1/31/2023	N/A	-27	-18	-18	N/A
10/31/2022	N/A	-24	-15	-14	N/A
7/31/2022	N/A	-18	-12	-12	N/A
4/30/2022	N/A	-14	-9	-9	N/A
1/31/2022	N/A	-11	-8	-8	N/A
10/31/2021	N/A	-7	-7	-7	N/A
7/31/2021	N/A	-6	-6	-6	N/A
4/30/2021	N/A	-5	-6	-5	N/A
1/31/2021	N/A	-5	-5	-4	N/A
10/31/2020	N/A	-5	-5	-4	N/A
7/31/2020	N/A	-6	-6	-5	N/A
4/30/2020	N/A	-6	-5	-5	N/A
1/31/2020	N/A	-5	-5	-5	N/A
10/31/2019	N/A	-4	-4	-4	N/A
7/31/2019	N/A	-3	-3	-3	N/A
4/30/2019	N/A	-3	-4	-4	N/A
1/31/2019	N/A	-4	-4	-4	N/A
10/31/2018	N/A	-4	-4	-4	N/A
7/31/2018	N/A	-4	-4	-3	N/A
4/30/2018	N/A	-3	N/A	-3	N/A
1/31/2018	N/A	-3	N/A	-3	N/A
10/31/2017	N/A	-3	N/A	-3	N/A
7/31/2017	N/A	-2	N/A	-3	N/A
4/30/2017	N/A	-2	N/A	-3	N/A
1/31/2017	N/A	-2	N/A	-3	N/A
10/31/2016	N/A	-2	N/A	-3	N/A
7/31/2016	N/A	-3	N/A	-2	N/A
4/30/2016	N/A	-3	N/A	-2	N/A
1/31/2016	N/A	-3	N/A	-2	N/A
10/31/2015	N/A	-3	N/A	-2	N/A
7/31/2015	N/A	-3	N/A	-2	N/A
4/30/2015	N/A	-3	N/A	-2	N/A
1/31/2015	N/A	-3	N/A	-2	N/A
10/31/2014	N/A	-3	N/A	-2	N/A
7/31/2014	N/A	-3	N/A	-1	N/A
4/30/2014	N/A	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que SVA sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que SVA sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que SVA sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (60.2% al año) de SVA crezcan más rápidamente que los del mercado Canadian (7.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (60.2% al año) de SVA crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de SVA se prevé que sea elevada dentro de 3 años.

Sernova Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2027

Price target decreased by 18% to CA$2.88

Price target decreased by 14% to CA$3.52

Price target decreased by 13% to CA$3.53

Price target decreased by 16% to CA$3.52

Price target increased to CA$4.21

Recent updates

Forecast to breakeven in 2027

Sernova Corp. Appoints James Parsons as Chief Financial Officer

Price target decreased by 18% to CA$2.88

Sernova Corp. Announces New Positive Data from Phase I/II Trial Regarding Islet Survival and Function

Sernova Corp. announced that it has received CAD 5.2 million in funding

Independent Director recently sold CA$223k worth of stock

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Sernova Corp. announced that it expects to receive CAD 4 million in funding

Price target decreased by 14% to CA$3.52

Less than half of directors are independent

Sernova Corp. Appoints Jonathan Rigby as Executive Chairman

Sernova Corp. Appoints Jonathan Rigby to Board of Directors

New minor risk - Share price stability

New minor risk - Market cap size

Price target decreased by 13% to CA$3.53

Sernova Corp., Annual General Meeting, Apr 30, 2024

New minor risk - Financial position

Companies Like Sernova (TSE:SVA) Are In A Position To Invest In Growth

Sernova Corp. Announces New Advancements of Conformal Coating Technology in Combination with the Cell Pouch System™ at the 2023 IPITA-IXA-CTRMS Joint Congress

Sernova Announces Positive Ongoing Interim Phase 1/2 Clinical Data for the Cell Pouch System™ for Type 1 Diabetes Trial at the 2023 IPITA, IXA, and CTRMS Joint Congress

Sernova Corp. Announces New Preclinical Data for its Novel Cell Therapy Platform, Cell Pouch System, as Potential Treatment for Post-Operative Hypothyroidism at 2023 American Thyroid Association Annual Meeting

Price target decreased by 16% to CA$3.52

Sernova Corp. Provides Development Update on Proprietary Cellular Conformal Coating Technology in Combination with Cell Pouch Device

Sernova Corp. Appoints Cynthia Pussinen as Chief Executive Officer

We're Keeping An Eye On Sernova's (TSE:SVA) Cash Burn Rate

Chairman recently bought CA$238k worth of stock

Sernova Corp Appoints Modestus Obochi as Chief Business Officer

Sernova Corp. Announces Positive Updated Interim Phase 1/2 Clinical Data for the Cell Pouch System™? at American Diabetes Association 83rd Scientific Sessions

New major risk - Financial position

Sernova Corp. Announces Executive Changes

Less than half of directors are independent

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp., Annual General Meeting, Apr 27, 2023

Sernova Announces Advancements with Its Novel Cell Pouch System™ to Preserve Thyroid Function Following Total Thyroidectomy

Sernova Corp. Announces Executive Changes

Sernova Announces First Two Patients Implanted with Cell Pouch™ in the Second Cohort of Its US Phase 1/2 Clinical Trial for Type 1 Diabetes

Price target increased to CA$4.21

Sernova Receives Authorization to Enroll Second Patient Cohort of Phase 1/2 Trial with Cell Pouch System™ for Type 1 Diabetes

We Think Sernova (TSE:SVA) Can Afford To Drive Business Growth

Sernova Corp. Appoints Daniel Mahony, Ph.D. to Its Board of Directors, Effective from September 30, 2022

Executive Chairman of the Board recently bought CA$65k worth of stock

Sernova Corp. Announces Positive Updated Phase 1/2 Clinical Data on Cell Pouch System Tm at American Diabetes Association 82nd Scientific Sessions 2022

Sernova Corp.(TSXV:SVA) dropped from S&P/TSX Venture Composite Index

Sernova Corp. announced that it has received CAD 20.323499 million in funding from Evotec SE

Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation At American Diabetes Association 82Nd Scientific Sessions 2022

No longer forecast to breakeven

Here's Why We're Not At All Concerned With Sernova's (CVE:SVA) Cash Burn Situation

Sernova Corp., Annual General Meeting, Apr 28, 2022

Sernova Corp. Announces Publication of A Peer Reviewed Preclinical Study Demonstrating Positive Results of A Novel Cell Pouch System Cell Therapy

Sernova Corp. Provides Progress Update on Its Phase 1/2 T1d Clinical Trial

Sernova to Announce New Interim Results of its Type 1 Diabetes Clinical Trial During the 40th Annual J.P. Morgan Healthcare Conference

Sernova Announces Clinical Investigator Update of its Type 1 Diabetes Trial at the 2022 ASTS 22nd Annual Winter Symposium

Forecast to breakeven in 2024

We Think Sernova (CVE:SVA) Can Easily Afford To Drive Business Growth

Sernova's Principal Investigator Presents Positive New Data from Ongoing Type 1 Diabetes (T1D) Clinical Trial at ATC 2021 Virtual Connect Conference

Chief Financial Officer recently bought CA$78k worth of stock

Sernova Corp. has completed a Composite Units Offering in the amount of CAD 20.04 million.

Sernova Corp Announces Second Annual Data Safety Monitoring Board Review of its Diabetes Cell Pouch System Clinical Trial and Recommendation for Protocol Continuation

Independent Chairman exercised options to buy CA$272k worth of stock.

Sernova Corp. Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

New 90-day high: CA$0.75

New 90-day high: CA$0.57

New 90-day high: CA$0.31

Sernova Corp. Provides Clinical Update on U.S. Phase I/II Cell Pouch Trial for Type 1 Diabetes

New 90-day low: CA$0.26

Sernova Corp. announced that it has received CAD 3.6655 million in funding

Sernova Corp. announced that it expects to receive CAD 3 million in funding

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas